Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

January 29, 2024

https://www.globenewswire.com/news-release/2024/01/29/2818922/0/en/Vaxcyte-Completes-Enrollment-of-Phase-1-2-Study-Evaluating-VAX-31-for-the-Prevention-of-Invasive-Pneumococcal-Disease-IPD-in-Adults-Aged-50-and-Older.html

— Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 —

— VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in the U.S. Adult Population —

Read more at globenewswire.com

Related news for (PCVX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.